A Phase 1, Participant- and Investigator-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Doses of LY3985863 in Healthy Chinese Participants
Latest Information Update: 27 Jun 2025
At a glance
- Drugs Bimagrumab (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 27 Jun 2025 New trial record